Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.

from http://ambrx.com

Publications show all

Ambrx has published 11 articles.

Patents show all

459Applications239Issued

Clinical Trials show all

1Phase 11Phase 2

SEC Filings show all

D2S-11

Private Funding Events

DateOfferedSoldType
2009-04-01$10,000,000$10,000,000Equity
2006-07-27UnknownUnknownOther (Paper Filing)

Key Executives

  • Stephen W. Kaldor
    Executive Officer, Director
  • Douglas W. Axelrod
    Executive Officer
  • Crispina Calsada
    Executive Officer
  • Ho Sung Cho
    Executive Officer
  • Kevin L. Eastwood
    Executive Officer
  • John W. Wallen, III
    Executive Officer
  • John D. Diekman
    Director
  • Richard D. DiMarchi
    Director
  • Shehan Dissanayake
    Director
  • Allan Marchington
    Director
  • Peter G. Schultz
    Director
  • David B. Singer
    Director
  • August M. Watanabe
    Director